Calico enters into agreement with the Buck Institute to conduct research into the biology of aging and to identify potential therapeutics for age-related diseases

Calico, a company focused on aging research and therapeutics, and the Buck Institute for Research on Aging have partnered to support research into longevity and age-related diseases. Financial terms have not been disclosed.

Under the agreement, Calico will have the opportunity to identify, fund and support innovative research, ranging from basic biology to potential therapies for age-related diseases. Calico has the option to obtain exclusive rights to discoveries made under research it supports. Additionally, Calico will establish and maintain certain science operations at the Buck.

“We are excited to forge this new partnership with Calico, which represents a unique way for academic researchers focused on aging and the biotech industry to work together,” said Brian K. Kennedy, PhD, Buck Institute President and CEO. “It’s a great partnership between two organizations aimed at helping people live longer healthier lives, and we look forward to collaborating with their team.”

Commented Hal Barron, President of Research and Development at Calico. “Given the Buck’s exclusive focus on aging, we believe that there’s great potential to increase our understanding of the biology of aging and to accelerate the translation of emerging insights into therapies to help patients with age-related diseases.”

About Calico

Calico (Calico Life Sciences LLC) is a Google-founded research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. Calico will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Visit www.calicolabs.com